MannKind Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de MannKind de 39.2% y 15.9% respectivamente, mientras que el BPA crecerá en un 38.6% al año.

Información clave

39.2%

Tasa de crecimiento de los beneficios

38.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	23.7%
Tasa de crecimiento de los ingresos	15.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	29 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

Mar 03

MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Mar 02

MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

Jan 27

Mannkind Corporation: Ready For Your Biotech Portfolio

Sep 01

New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

Aug 19

MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed

Aug 09

MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?

Feb 25

MannKind: A Promising Player In The Inhalable Insulin Market

Feb 08

US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

Aug 14

Lytham Partners Summer 2021 Investor Conference

Jun 14

MannKind (MNKD) Investor Presentation - Slideshow

Jun 04

MannKind reduces debt by $49.5M and restructures remaining obligations

Apr 26

Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?

Feb 22

MannKind to co-promote Thyquidity

Dec 17

MannKind (MNKD) earns $12.5M milestone under licensing deal for treprostinil

Nov 20

MannKind: Global Product Sales, Late-Stage Clinical Pipeline Candidate, And Strong Leadership, 34% Upside

Nov 03

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:MNKD - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	378	125	167	N/A	5
12/31/2025	313	74	126	N/A	6
12/31/2024	260	39	188	N/A	5
12/31/2023	199	-12	-8	34	N/A
9/30/2023	177	-31	-32	10	N/A
6/30/2023	158	-47	-57	-27	N/A
3/31/2023	128	-71	-72	-61	N/A
12/31/2022	100	-87	-88	-81	N/A
9/30/2022	76	-98	-98	-91	N/A
6/30/2022	66	-88	-89	-78	N/A
3/31/2022	70	-94	-83	-67	N/A
12/31/2021	75	-81	-73	-62	N/A
9/30/2021	81	-79	-60	-49	N/A
6/30/2021	75	-86	-54	-47	N/A
3/31/2021	66	-61	-35	-30	N/A
12/31/2020	65	-57	-33	-28	N/A
9/30/2020	63	-45	-34	-33	N/A
6/30/2020	62	-44	-73	-72	N/A
3/31/2020	62	-46	-91	-88	N/A
12/31/2019	63	-52	-91	-88	N/A
9/30/2019	63	-47	-61	-58	N/A
6/30/2019	53	-61	-22	-20	N/A
3/31/2019	42	-71	-28	-28	N/A
12/31/2018	28	-87	-38	-38	N/A
9/30/2018	16	-110	-93	-93	N/A
6/30/2018	13	-119	-102	-102	N/A
3/31/2018	12	-131	-95	-95	N/A
12/31/2017	11	-117	-65	-65	N/A
9/30/2017	20	-31	N/A	-48	N/A
6/30/2017	180	129	N/A	-47	N/A
3/31/2017	178	134	N/A	-39	N/A
12/31/2016	175	126	N/A	-78	N/A
9/30/2016	162	-205	N/A	-88	N/A
6/30/2016	N/A	-364	N/A	-85	N/A
3/31/2016	N/A	-363	N/A	-91	N/A
12/31/2015	N/A	-368	N/A	-57	N/A
9/30/2015	N/A	-128	N/A	-70	N/A
6/30/2015	N/A	-133	N/A	50	N/A
3/31/2015	N/A	-177	N/A	44	N/A
12/31/2014	N/A	-198	N/A	4	N/A
9/30/2014	N/A	-216	N/A	6	N/A
6/30/2014	N/A	-230	N/A	-127	N/A
3/31/2014	N/A	-203	N/A	-134	N/A
12/31/2013	N/A	-191	N/A	-129	N/A
9/30/2013	N/A	-190	N/A	-123	N/A
6/30/2013	0	-182	N/A	-124	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que MNKD sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que MNKD sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que MNKD sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (15.9% al año) de MNKD crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 15.9% al año) de MNKD crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MNKD se prevé que sea elevada dentro de 3 años.

MannKind Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 9.8% to US$7.25

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 8.1% to US$6.67

Consensus forecasts updated

Price target decreased to US$5.50

Consensus estimates of losses per share improve by 15%

Recent updates

MannKind Corporation to Report Q1, 2024 Results on May 08, 2024

MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases

MannKind Corporation, Annual General Meeting, May 15, 2024

MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024

MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024

MannKind Corporation Announces INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps

This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year

MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Full year 2023 earnings: EPS and revenues exceed analyst expectations

MannKind Corporation to Report Q4, 2023 Results on Feb 27, 2024

MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®

MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation

MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking

CEO & Director notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

MannKind Corporation Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living with Type 1 Diabetes

MannKind Corporation to Report Q3, 2023 Results on Nov 07, 2023

Price target increased by 9.8% to US$7.25

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

MannKind Corporation to Report Q2, 2023 Results on Aug 07, 2023

Mannkind Corporation Launches Inhale-3 Study to Address the Most Important Unmet Need in Adults Living with Type 1 Diabetes (T1d)

CEO & Director notifies of intention to sell stock

Dr. Burkhard Blank Joins MannKind Corporation as Executive Vice President of Research & Development and Chief Medical Officer

Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 8.1% to US$6.67

Full year 2022 earnings: EPS misses analyst expectations

MannKind Corporation to Report Q4, 2022 Results on Feb 23, 2023

MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price

MannKind Corporation Announces its Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Mannkind Corporation Announces Resignation of Alejandro Galindo as Executive Vice President – Endocrine Business Unit, Effective October 21, 2022

MannKind Corporation Successfully Completes Phase 1 Study of Inhaled Clofazimine

Mannkind Corporation: Ready For Your Biotech Portfolio

New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed

MannKind Corporation to Report Q2, 2022 Results on Aug 09, 2022

MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™

Price target decreased to US$5.50

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

Consensus estimates of losses per share improve by 15%

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

High number of new directors

MannKind Corporation, Annual General Meeting, May 10, 2022

Consensus revenue estimates fall by 12%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

MannKind Corporation Provides Update on Tyvaso DPI New Drug Application

MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?

MannKind Corporation to Report Q4, 2021 Results on Feb 24, 2022

MannKind: A Promising Player In The Inhalable Insulin Market

Forecast to breakeven in 2024

Price target increased to US$6.25

Third quarter 2021 earnings released: US$0.018 loss per share (vs US$0.049 loss in 3Q 2020)

Price target decreased to US$5.80

No longer forecast to breakeven

Consensus forecasts updated

High number of new and inexperienced directors

Consensus forecasts updated

US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.048 loss in 2Q 2020)

Lytham Partners Summer 2021 Investor Conference

MannKind (MNKD) Investor Presentation - Slideshow

Consensus forecasts updated

First quarter 2021 earnings released: US$0.052 loss per share (vs US$0.044 loss in 1Q 2020)